ACIST Medical Systems has announced that it has entered into a strategic agreement with Medtronic to co-promote the world’s first Rapid Exchange FFR (RXi) and High Definition IVUS (HDi) technologies in the United States. Under this agreement, ACIST and Medtronic will work collaboratively to introduce these products into cardiac catheterisation laboratories across the USA.
FFR (Fractional Flow Reserve) has quickly become the standard that interventional cardiologists use to determine which patients can most benefit from stenting. IVUS (intravascular ultrasound) is an advanced diagnostic modality that provides greater insight into arterial disease than standard angiography alone. The ACIST Rapid FFR (RXi) and High Definition IVUS (HDi) systems are quicker, easier to use and offer detailed insight that physicians can use to optimise treatment choice for their patients.
“This partnership is a significant milestone in the transformation of ACIST, and will help us to achieve rapid and significant penetration of the U.S. market,” says Tom Morizio, president and chief operating officer, ACIST Medical Systems. “Medtronic is a worldwide leader in delivering new and innovative medical technologies. Our products are an excellent complement to their interventional cardiology product portfolio. We see great benefits and potential in working with Medtronic to increase our share of voice and field presence through this agreement, and look forward to maximising the awareness of these products in the USA.”
ACIST’s new Rapid FFR system, which utilizes the ultra-thin ACIST Navvus Rapid Exchange MicroCatheter and RXi console, was introduced earlier this year in the United States and Europe. The Navvus MicroCatheter can be used over a standard 0.014 inch guidewire, and the RXi system facilitates rapid FFR assessments before, during and post-intervention. This unique technology is the first of its kind, providing the reassurance of accurate and reliable FFR measurements and the advantages of Rapid Exchange technology.